Next Article in Journal
In-Hospital Palliative Care: Should We Need to Reconsider What Role Hospitals Should Have in Patients with End-Stage Disease or Advanced Cancer?
Next Article in Special Issue
Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of β-Interferon Treatment
Previous Article in Journal
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Previous Article in Special Issue
Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson’s Disease

Biomarkers for Detecting Mitochondrial Disorders

by 1,*,† and 2,†
Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, Austria
El Manar and Genomics Platform, Pasteur Institute of Tunis, University of Tunis, Tunis 1068, Tunisia
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Clin. Med. 2018, 7(2), 16;
Received: 9 December 2017 / Revised: 28 December 2017 / Accepted: 19 January 2018 / Published: 30 January 2018
(1) Objectives: Mitochondrial disorders (MIDs) are a genetically and phenotypically heterogeneous group of slowly or rapidly progressive disorders with onset from birth to senescence. Because of their variegated clinical presentation, MIDs are difficult to diagnose and are frequently missed in their early and late stages. This is why there is a need to provide biomarkers, which can be easily obtained in the case of suspecting a MID to initiate the further diagnostic work-up. (2) Methods: Literature review. (3) Results: Biomarkers for diagnostic purposes are used to confirm a suspected diagnosis and to facilitate and speed up the diagnostic work-up. For diagnosing MIDs, a number of dry and wet biomarkers have been proposed. Dry biomarkers for MIDs include the history and clinical neurological exam and structural and functional imaging studies of the brain, muscle, or myocardium by ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), MR-spectroscopy (MRS), positron emission tomography (PET), or functional MRI. Wet biomarkers from blood, urine, saliva, or cerebrospinal fluid (CSF) for diagnosing MIDs include lactate, creatine-kinase, pyruvate, organic acids, amino acids, carnitines, oxidative stress markers, and circulating cytokines. The role of microRNAs, cutaneous respirometry, biopsy, exercise tests, and small molecule reporters as possible biomarkers is unsolved. (4) Conclusions: The disadvantages of most putative biomarkers for MIDs are that they hardly meet the criteria for being acceptable as a biomarker (missing longitudinal studies, not validated, not easily feasible, not cheap, not ubiquitously available) and that not all MIDs manifest in the brain, muscle, or myocardium. There is currently a lack of validated biomarkers for diagnosing MIDs. View Full-Text
Keywords: biomarker; diagnosis; mitochondrial disorder; mtDNA; oxidative phosphorylation; ATP biomarker; diagnosis; mitochondrial disorder; mtDNA; oxidative phosphorylation; ATP
MDPI and ACS Style

Finsterer, J.; Zarrouk-Mahjoub, S. Biomarkers for Detecting Mitochondrial Disorders. J. Clin. Med. 2018, 7, 16.

AMA Style

Finsterer J, Zarrouk-Mahjoub S. Biomarkers for Detecting Mitochondrial Disorders. Journal of Clinical Medicine. 2018; 7(2):16.

Chicago/Turabian Style

Finsterer, Josef, and Sinda Zarrouk-Mahjoub. 2018. "Biomarkers for Detecting Mitochondrial Disorders" Journal of Clinical Medicine 7, no. 2: 16.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop